FIELD: medicine.
SUBSTANCE: Irinotecan, Cisplatin and Aranose are introduced sequentially in doses making 1/4 of maximum tolerated every 10-20 minutes in two-fold or three-fold administration regimen.
EFFECT: method provides antitumourigenesis ensured by combined effect of the preparations and improved therapy tolerance.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
METHOD OF TREATING LUNG CANCER | 2009 |
|
RU2414894C1 |
INHIBITORS OF CELL CYCLE CHECKPOINT KINASE 1 FOR AMPLIFICATION OF DNA-DAMAGING AGENTS | 2010 |
|
RU2567044C2 |
METHOD OF TREATING COLON CANCER | 2012 |
|
RU2529831C2 |
METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
COMBINATION OF DEHYDROXYMETHYL EPOXYQUINOMYCIN (DHMEQ) AND CYTOSTATICS FOR TREATING OVARIAN CANCER | 2018 |
|
RU2704020C1 |
AGENT INTENSIFYING ACTION OF ANTI-CANCER AGENTS | 2012 |
|
RU2589713C2 |
ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
Authors
Dates
2009-09-20—Published
2008-05-26—Filed